Moteur de recherche d’entreprises européennes
Financement de l’UE (2 514 575 €) : Le premier pansement bioactif - exploitant les propriétés uniques de cicatrisation des plaies et antimicrobiennes du collagène humain VI Hor 01/05/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Le premier pansement bioactif - exploitant les propriétés uniques de cicatrisation des plaies et antimicrobiennes du collagène humain VI
Chronic wounds are a global problem. They severely impair the quality of life for 200 million patients worldwide and generate vast medical costs. It is a problem that will only escalate with the increasing incidence of conditions that impede wound healing, such as diabetes, obesity and vascular disorders. The available wound care options can manipulate one or multiple aspects of the wound environment but cannot form antibacterial barriers and facilitate healing to a satisfactory level at the same time. Effective wound care products to address both: rapid wound closure and combat of infection are, therefore, urgently needed. Colzyx aims to address the unmet challenges in wound management with its novel wound dressing. Basing on a ground-breaking discovery of wound healing and antimicrobial properties of human collagen VI and parts thereof, Colzyx has developed a product that has the potential to revolutionise wound management and create a new category of bioactive wound dressings. WOUNDCOM uses highly functional molecules that promote wound healing by mimicking natural body mechanisms and at the same time combat bacterial infection. This approach offers significant benefits to patients through reduction of pain and discomfort and accelerated recovery. It will also shorten hospitalisation time and decrease the associated financial burden. This project’s objective is to validate the efficacy and safety of WOUNDCOM and bring it to commercial readiness. The project builds on our SMEi Phase 1 project, which provided a valuable understanding of the current trends and opportunities on the wound management market, targeted users, competitors and potential partnerships. The feasibility study was used to optimise the business plan and prepare a synopsis for the clinical study. Successful evaluation of WOUNDCOM’s in the clinic will enable CE marking and support building the awareness and continued strategic partnerships for product manufacturing, marketing, and distribution.
| Colzyx AB | 2 514 575 € |
https://cordis.europa.eu/project/id/947034
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Colzyx AB, Lund, Suède.
